11月2日,复宏汉霖公布其PD-L1 ADC(HLX43)用于治疗非小细胞肺癌(NSCLC)的关键更新数据。截至2025年10月22日,研究共纳入174例晚期NSCLC患者,其中接受2.0 mg/kg HLX43静脉注射治疗的患者为89例,接受2.5 mg/kg 治疗的患者为85例。全部患者接受过铂类药物治疗,约80%和逾30%的患者分别接受过免疫治疗和靶向治疗,部分患者接受过多西他赛治疗,均为...
Source Link11月2日,复宏汉霖公布其PD-L1 ADC(HLX43)用于治疗非小细胞肺癌(NSCLC)的关键更新数据。截至2025年10月22日,研究共纳入174例晚期NSCLC患者,其中接受2.0 mg/kg HLX43静脉注射治疗的患者为89例,接受2.5 mg/kg 治疗的患者为85例。全部患者接受过铂类药物治疗,约80%和逾30%的患者分别接受过免疫治疗和靶向治疗,部分患者接受过多西他赛治疗,均为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.